Monograph Details
|
|
Poisoning & Drug Dependence
> Smoking
|
|
CHANTIX |
| Manufacturer |
|
Pfizer Labs |
| Legal Classification |
|
Rx
|
| Pharmacological Class |
|
α4β2 nicotinic acetylcholine receptor partial agonist. |
| Generic Name |
|
Varenicline (as tartrate) 0.5mg, 1mg; tabs. |
| Indications |
|
Smoking cessation aid. |
| Children |
|
<18yrs: not recommended. |
| Adults |
|
Provide patients with counseling and educational support. Set a target "quit date". Begin therapy 1 week before target quit date. Take after eating with a glass of water. ≥18yrs: initially 0.5mg once daily for 3 days, then 0.5mg twice daily for 4 days, then 1mg twice daily. May reduce dose if intolerable nausea or other adverse effects occur. Treat for 12 weeks; may continue 12 more weeks if patient successfully stops smoking to further increase the likelihood of abstinence. Severe renal impairment: initially 0.5mg once daily; may titrate to max 0.5mg twice daily. End stage renal disease with hemodialysis: max 0.5mg once daily if tolerated. Reevaluate if abstinence is not achieved after 1st 12 weeks. |
| Precautions |
|
Psychiatric disorders (monitor). Renal impairment. Pregnancy (Cat.C). Nursing mothers: not recommended. |
| Interactions |
|
Smoking cessation may affect metabolism of other drugs (eg, warfarin, theophylline, insulin). Increased adverse effects with nicotine replacement therapy. |
| Adverse Reactions |
|
Nausea, other GI effects (eg, constipation, flatulence, vomiting), sleep disturbance (eg, abnormal dreams, insomnia), headache; nicotine withdrawal symptoms (due to smoking cessation); serious neuropsychiatric symptoms (eg, behavioral changes, agitation, depression, suicidal ideation). |
| How Supplied |
Tabs—56
Starting Month PAK (0.5mg x 11 tabs + 1mg x 42 tabs)—1
Continuing Month PAK (1mg x 56 tabs)—1 |
|
|
|
|
